Breast Cancer Home > Halaven Drug Interactions
When chemotherapy medications or QT-prolonging drugs are combined with Halaven, negative interactions may occur. Some of these reactions can lead to potentially serious side effects, such as low white blood cells, anemia, and changes in heart rhythm. To avoid these complications, be sure to talk to your healthcare provider prior to receiving this drug about specific interactions that may apply to you.
An Overview of Interactions with HalavenHalaven™ (eribulin mesylate) is a prescription medication licensed to treat breast cancer. This medication may react with certain other medications.
Some of the drugs that may lead to interactions with Halaven include but are not limited to:
- Other chemotherapy medications
- Medications that can cause a specific change in the heart rhythm known as QT prolongation (see QT-Prolonging Medications for a list of such medications).
Halaven Drug Interactions ExplainedThe following sections explain in detail the potentially negative interactions that can occur when Halaven is combined with any of the drugs listed above.
Other Chemotherapy Medications
Most chemotherapy medications have a tendency to cause similar serious side effects, such as low white blood cells, nausea, and anemia. Combining Halaven with other chemotherapy drugs might increase the risk of severe side effects. Your healthcare provider will take this into account when anticipating and treating any side effects that may occur.
In studies, Halaven was shown to potentially cause a change in heart rhythm known as QT prolongation. This is a potentially serious change that can lead to life-threatening arrhythmias. Combining Halaven with other QT-prolonging medications probably increases the risk. If you must combine Halaven with other QT-prolonging medications, your healthcare provider should closely monitor your heart rhythm.